Venture Valuation presented a preview of its new report together with KPMG “Site Selection for Life Sciences Companies: Cluster Report 2015” in January at three locations including during JPMorgan in San Francisco, in Singapore and Taipei in February. The new report will be published in May 2015. For a copy of the key slides, please … Continue reading Preview. Site Selection for Life Sciences Companies: Cluster Report 2015
Big acquisitions like the recent purchase by Roche, Switzerland of Intermune, USA or AbbVie‘s successful USD 54bn bid for Shire, Ireland, are very good examples of how valuation metrics work and also show that often its not just about price. In case of AbbVie/Shire, potential tax saving was probably the key deal driver. In the … Continue reading Biotech Product Valuation – Setting a Price for Acquisitions
September 2014: Financing is an ongoing challenge for all Biotech companies. Without sufficient resources, products cannot be advanced in the development. Scarce resources help companies to focus as it is more important to bring one or two products into the clinic than advancing five different programs in pre-clinical development. But many European companies are struggling … Continue reading How to raise sufficient funds for Biotechs?
Venture Valuation recently published an article in Nature Biotechnology 32, 617–619, (2014) based on data from its Biotechgate deals database looking at the difference between big pharma and SMEs in the upfront payments and number of deals. Read more here (Nature Biotechnology) To get access to Biotechgate, please contact us here. Source: Nature Biotechnology, 32, … Continue reading The premium of a big pharma license deal
Marketing alliances between well-known brand names and consumer products have long been a tradition for example Michael Jackson and Pepsi or George Clooney and Nespresso. Soccer clubs are also dependent on sponsor income and are working with many different industries like telecoms, airlines and insurances. Now prestigious Manchester United (Man U) has signed a marketing … Continue reading Soccer and Pharma/BIOtech
Orphan drugs have been en vogue for a while. However, in the last quarter there has been a record financing that has put drugs for small patient populations on the map even more. In Q1 2014, over 60% of the financing in European Biotech has gone to companies that have a lead orphan drug product. … Continue reading Is Orphan saving Biotech?
Are you wondering what investors still have money and are investing? At Biotechgate we are tracking all financing of investors and we also run a global database of what investors are looking for. As an example, the following investors have made investments into European Health Care companies in Q1 2014: AT NewTec, Germany Boehringer Ingelheim … Continue reading Who is investing and who is not?
With the announcement of the portfolio transformation of Novartis this month, we believe this will have a positive impact on the biotech industry. The company will focus on Pharmaceuticals, Eye Care and Generics. The diversification strategy of former CEO and Chairman Daniel Vasella has been axed by the new leadership of Novartis. Key components of … Continue reading What is the impact of Novartis transformation on biotech industry?
Even with the public biotech was just at an all time high, VCs in the US also have difficulties convincing LPs (Limited Partners) to make investment in their funds. At a recent panel discussion led by Venture Valuation at the RESI (redefining early stage investment) conference in Boston, VCs offered an insight into their perspective … Continue reading Early stage VC funding in the US more difficult than ever
Does it make sense for a life science fundraising executive in Europe to look internationally for early-stage funding? Should U.S. based firms look at investors in Europe and Asia? As the famous folk singer Bob Dylan sang “the times they are a changing” and the answer is yes! To someone looking to fund a … Continue reading Global, Early-Stage Investors in Emerging Life Science Companies
